Horan Christopher 4

What Happened
Christopher Horan, Artiva Biotherapeutics' Chief Tech Operations Officer, was granted 117,300 restricted stock units (RSUs) on February 15, 2026 (transaction code A). The filing also reports 2,187 shares were withheld by the company to satisfy income tax obligations on vesting (transaction code F) at an indicated withholding price of $4.00 per share, totaling $8,748. The RSU grant itself shows an acquisition value of $0 on the Form 4 because awards are recorded as grants rather than open-market purchases.

Key Details

• Transaction dates: February 15, 2026 (award grant and tax-withholding). Form 4 filed February 18, 2026.
• Grant: 117,300 RSUs (transaction code A) — recorded at $0 on Form 4 as an equity award.
• Tax withholding: 2,187 shares withheld (transaction code F) at $4.00/share = $8,748 (reported as a disposition).
• Footnotes: F1 — RSU award under the Issuer's 2024 Equity Incentive Plan; F2 — shares withheld to satisfy income tax obligations on RSU vesting.
• Shares owned after the transaction are not specified in the supplied excerpt of the filing.
• Timeliness: Filing date is Feb 18 for a Feb 15 transaction; depending on business-day counting this may fall outside the usual 2-business-day Form 4 reporting window.

Context

• This is a compensation-related award (RSUs), not an open-market purchase or a voluntary sale. Such grants are common for executive compensation and do not by themselves indicate buying or selling sentiment.
• The 2,187-share disposition is purely for tax withholding on the vesting award (a routine, mechanical transaction), not a market sale.
• For retail investors: track future vesting or sale events if you want to assess any trading-driven supply or insider conviction; awards signal compensation alignment but are not direct buy/sell endorsements.